On October 19, the State Drug Administration held a conference to promote “artificial intelligence+drug supervision”. Huang Guo, Party Secretary and Director of the State Drug Administration, attended the meeting and delivered a speech. The conference pointed out that artificial intelligence is a key variable affecting future development. It is deeply penetrating the entire chain of drug research and development, production, circulation, and use, profoundly changing the shape and risk structure of the industry. The conference emphasized the need to establish rules, stabilize expectations, strengthen services, cultivate ecology, and actively promote artificial intelligence to empower innovation and development in the pharmaceutical industry based on supervisory responsibilities. Special plans should be formulated to support key tracks to take the lead in breakthroughs, move review services to the source of innovation, and create a regulatory environment that encourages innovation and is inclusive and prudent. Artificial intelligence should be used to raise the level of drug safety management, promote smarter review and approval, more accurate inspection and enforcement, more sensitive risk prevention and control, and more efficient collaborative supervision. It is necessary to consolidate basic guarantees, establish an artificial intelligence application management mechanism covering the full cycle and continuous iteration, strengthen resource coordination, train a team of professional talents, promote “technology for good”, and maintain the bottom line of artificial intelligence safety.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.